Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Povorcitinib
Sponsor:Incyte Corp.

Contact Research Centre

Dermatitis atopic

Recruiting

Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

Investigational

Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:APG777
Sponsor:Apogee Therapeutics Inc.

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Palmoplantar pustulosis

Recruiting

Study of Delgocitinib Cream for Adults with Mild to Severe Palmoplantar Pustulosis: A 16-Week Treatment Trial

Investigational

Study of Delgocitinib Cream for Adults with Mild to Severe Palmoplantar Pustulosis: A 16-Week Treatment Trial

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Leo Pharma A/S

Contact Research Centre

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:BI 1291583
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Kiel

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of ribociclib with endocrine therapy for HR-positive, HER2-negative cases. Additional research encompasses various blood cancers, including lymphomas and leukemia.

Early-stage breast cancer therapy
Diffuse large B-cell lymphoma treatments
Acute myeloid leukemia management

Cutting-edge research evaluating novel therapeutic combinations and treatment approaches for better patient outcomes.

02 Dermatological Studies

Comprehensive research into chronic skin conditions, including trials for plaque psoriasis and atopic dermatitis. Studies evaluate new therapeutic agents for moderate to severe cases.

Hidradenitis suppurativa treatments
Novel psoriasis therapies
Atopic dermatitis management

Focus on developing effective treatments for persistent skin conditions that significantly impact quality of life.

03 Gastrointestinal Research

Advanced studies in inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Trials investigate innovative therapies for moderate to severe cases.

Long-term disease management
Combination therapy approaches
Treatment-resistant cases

Investigation of new therapeutic options for patients with inadequate response to conventional treatments.

Back to Germany All countries